241 related articles for article (PubMed ID: 22996961)
1. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.
Castellarin M; Milne K; Zeng T; Tse K; Mayo M; Zhao Y; Webb JR; Watson PH; Nelson BH; Holt RA
J Pathol; 2013 Mar; 229(4):515-24. PubMed ID: 22996961
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
[TBL] [Abstract][Full Text] [Related]
3. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
4. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
5. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
6. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
Marchocki Z; Tone A; Virtanen C; de Borja R; Clarke B; Brown T; May T
J Ovarian Res; 2022 May; 15(1):50. PubMed ID: 35501919
[TBL] [Abstract][Full Text] [Related]
8. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
9. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
10. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
11. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
13. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
14. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
15. Acquired chemotherapy resistance in ovarian cancer.
Christie EL; Bowtell DDL
Ann Oncol; 2017 Nov; 28(suppl_8):viii13-viii15. PubMed ID: 29232469
[TBL] [Abstract][Full Text] [Related]
16.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
17. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
18. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
19. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract][Full Text] [Related]
20. Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.
Anglesio MS; O'Neill CJ; Senz J; Gilks CB; McCluggage WG
Histopathology; 2017 Dec; 71(6):1014-1017. PubMed ID: 28746984
[No Abstract] [Full Text] [Related]
[Next] [New Search]